Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
News Oct 09, 2015
Evotec AG has announced that it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute ("NCI"), Department of Health and Human Services. Under the terms of the agreement, Evotec will provide compound management services to the NCI Chemical Biology Consortium ("CBC") for a period of five years with a total estimated value of up to EUR 4.5 m ($ 4.9 m).
The NCI Chemical Biology Consortium contract will continue to provide to acquire, store, maintain and distribute the current library collection. This repository will form part of the CBC's drug discovery and development platform for new oncology therapeutics being researched by a consortium of primarily academic and non-profit institutions.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are pleased the NCI has elected to award Evotec this important contract to support the Chemical Biology Consortium, an important initiative in the discovery of new cancer treatments."
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Discovery of Exomeres Could Help Reveal How Cancer Cells SpreadNews
A new cellular messenger discovered by Weill Cornell Medicine scientists may help reveal how cancer cells co-opt the body's intercellular delivery service to spread to new locations in the body.READ MORE